The Myth of the Free Market for Pharmaceuticals
New England Journal of Medicine · 2024
DOI: 10.1056/nejmp2313400 ↗Kurz gefasst
Fachartikel in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Rena M Conti und 2 weiteren Autor:innen. Beteiligte Einrichtung: From the Questrom School of Business, Boston University, Boston (R.M.C.), and the Conference on Research in Income and Wealth (R.M.C.), the National …. Hauptthemen laut MEDLINE: Commerce, Drug Industry, Economics, Pharmaceutical, Pharmaceutical Preparations. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
The U.S. pharmaceutical market has always been influenced by government. The 2022 Inflation Reduction Act is the latest policy aiming to improve access and affordability while supporting innovation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Questrom School of Business, Boston University, Boston (R.M.C.), and the Conference on Research in Income and Wealth (R.M.C.), the National Bureau of Economic Research (R.G.F., D.M.C.), and the Department of Ec…
Zitieren
APA
Conti, R. M., Frank, R. G., & Cutler, D. M. (2024). The Myth of the Free Market for Pharmaceuticals. New England Journal of Medicine. https://doi.org/10.1056/nejmp2313400
Vancouver
Conti RM, Frank RG, Cutler DM. The Myth of the Free Market for Pharmaceuticals. New England Journal of Medicine. 2024. doi:10.1056/nejmp2313400
BibTeX
@article{Conti2024,
author = {Conti, Rena M and Frank, Richard G and Cutler, David M},
title = {The Myth of the Free Market for Pharmaceuticals},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejmp2313400}
}
EUVIMED